Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2024-09-19 00:00:00 ET · period of report 2024-09-18 · accession 0001415889-24-023712 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-19 | 2024-09-18 | SPRY | Karas Eric | Chief Commercial Off | S - Sale+OE | $14.00 | -10.0K | 5,693 | -64% | -$140.0K |
| D | 2024-09-19 | 2024-09-18 | SPRY | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +10.0K | 15.7K | +176% | +$15.0K |
| D | 2024-09-19 | 2024-09-18 | SPRY | Karas Eric | Chief Commercial Off | M - OptEx | $0.00 | -10.0K | 594.6K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-18 | S | D | 10,000 | $14.00 | 5,693 | D | — | — | |
| 2 | Common | Common Stock | 2024-09-18 | M | A | 10,000 | $1.50 | 15,693 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-09-18 | M | D | 10,000 | $0.00 | 594,588 | D | $1.50 · — to 2032-05-23 | 10,000 Common Stock | (F2) Immediately exercisable. |